Need professional-grade analysis? Visit stockanalysis.com
$437.97M
N/A
N/A
N/A
Shattuck Labs Inc (STTK) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $7.76, up 3.05% from the previous close.
Over the past year, STTK has traded between a low of $0.73 and a high of $7.76. The stock has gained 811.9% over this period. It is currently 960.1% above its 52-week low.
Shattuck Labs Inc has a market capitalization of $437.97M.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Side-by-side comparison against top Healthcare peers.